As FLT3-internal tandem duplication is a critical risk marker that directly impact prognostication and clinical management in acute myeloid leukemia [10, 11], and there is established clinical benefit of FLT3 inhibitor therapy in patients harboring an FLT3 mutation [15–17], FLT3 testing has become routine in the work-up of newly diagnosed acute myeloid leukemia, and likely will soon become standard for relapsed/refractory acute myeloid leukemia patients. The gene discussed is FLT3; the disease is acute myeloid leukemia.